May 28, 2017 7:09 PM ET

Biotechnology

Company Overview of CoLucid Pharmaceuticals, Inc.

Company Overview

CoLucid Pharmaceuticals, Inc., a biopharmaceutical company, develops small molecules for the acute treatment of migraine. Its lead product candidate is Lasmiditan, an oral tablet that is in Phase III clinical program for the acute treatment of migraine headaches in adults. The company is also developing IV lasmiditan, which is in Phase II clinical trial for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts. CoLucid Pharmaceuticals, Inc. is a subsidiary of Eli Lilly and Company.

222 Third Street

Suite 1320

Cambridge, MA 02142

United States

Founded in 2005

7 Employees

Phone:

857-285-6495

Key Executives for CoLucid Pharmaceuticals, Inc.

President and Director
Chief Financial Officer
Age: 41
Head of Clinical and Regulatory Operations
Age: 57
Head of Pharmaceutical Operations
Age: 53
Vice President, Treasurer and Director
Compensation as of Fiscal Year 2016.

CoLucid Pharmaceuticals, Inc. Key Developments

Colucid Pharmaceuticals Files Form 15

Colucid Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock, $0.001 par value per share under the Securities Exchange Act of 1934, as amended.

Colucid Pharmaceuticals, Inc. Announces Executive Changes; Announces Amendments to the Company Bylaws

Colucid Pharmaceuticals, Inc. announced In connection with the Merger, and pursuant to the terms of the Merger Agreement with Eli Lilly, each of Mark Corrigon, Martin W. Edwards, Alison Lawton, Luc Marengere, Thomas P. Mathers, Arthur M. Pappas and Marvin L. White resigned from his or her respective position as a member of the Board of Directors, and any committee thereof, of the company, effective at the Effective Time. Following the company merger and pursuant to the terms of the merger agreement, at the effective time, the directors of Eli Lilly as of immediately prior to the effective Time, Darren J. Carroll, Martin Bott and Joshua Smiley, became the directors of the company. The company following the merger and pursuant to the terms of the merger agreement, at the effective time, the officers of purchaser immediately prior to the effective time became the officers of the company following the effective time, with Darren J. Carroll appointed as President, Joshua Smiley appointed as Vice President and Treasurer, Bronwen Mantlo appointed as Secretary and David P. Lewis appointed as Vice President, Corporate Tax and Assistant Treasurer of the company. Pursuant to the terms of the merger agreement, at the effective time the certificate of incorporation of the company was amended and restated to read in its entirety in a form as mutually agreed by Lilly and the company and the bylaws were amended and restated to read in their entirety as the bylaws of Purchaser in effect immediately prior to the Effective Time.

NASDAQ Files Notification Of Delisting Of CoLucid Pharmaceuticals’ Shares From NASDAQ On Form 25 With SEC

In connection with the closing of the Merger, CoLucid Pharmaceuticals, Inc. notified the NASDAQ Stock Market (NASDAQ) on March 1, 2017 that the Merger was consummated and trading of the Shares on NASDAQ has been suspended. Accordingly, NASDAQ has filed a notification of delisting of the Shares from NASDAQ and deregistration of the Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (Exchange Act) on Form 25 with the SEC. CoLucid intends to file a certification on Form 15 with the SEC to cause CoLucid’s reporting obligations under Sections 13 and 15(d) of the Exchange Act to be suspended.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
January 18, 2017
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CoLucid Pharmaceuticals, Inc., please visit www.colucid.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.